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Microglia
Microglia originate from the yolk sac during primitive hematopoie-
sis. Their differentiation depends on the activity of the transcription 
factors PU.1 and interferon regulatory factor 8 (IRF8) (1–4), and their 
survival requires CSF1 receptor (CSF1R) signaling (5, 6). The brain 
maintains microglia levels via a finely tuned balance between local 
proliferation and apoptosis (7), without contributions from periph eral 
monocytes (8, 9). Microglia constitute 5%–12% of all glial cells in the 
rodent brain and 0.5%–16% in humans (10–12). Additionally, the 
microglia transcriptome varies across regions, reflecting their func-
tional diversity within the CNS (13). As the brain’s resident immune 
cells, microglia partake in the establishment of normal neuronal con-
nectivity and regulatory processes critical for CNS development (9), 
such as synaptic pruning, which ensures elimination of inappropri-
ate synapses to strengthen the appropriate ones based on neuronal 
activity and experience (9). In the adult brain, microglia are involved 
in modulating higher cognitive functions such as learning and mem-
ory (14, 15). Morphologically, microglia are classified as ramified 
(quiescent/resting), activated, or ameboid (phagocytotic). The 
dynamic processes of resting microglia actively monitor the CNS 
parenchyma (16, 17), and this surveillant phenotype in combina-
tion with a specific receptor repertoire facilitates rapid microglial 
responses to changes in the microenvironment (18, 19). Further, 
microglia play an important role in maintaining homeostasis by 
removing cellular debris, dying cells, or misfolded proteins (20–25).
Beyond M1 and M2 classification
Over a decade ago, a model described the mechanism of two 
opposite states of macrophage activation (26). The M1 (proin-
flammatory) state, characterized by production of inflammatory 
cytokines and nitric oxide (NO) via upregulation of inducible NO 
synthase 2 (iNOS/NOS2), was induced by IFN-γ and bacterial 
cell wall components such as LPS or peptidoglycan. In contrast, 
M2 polarization in macrophages was achieved by treatment 
with antiinflammatory cytokines such as IL-4 and IL-13, which 
induced upregulation of arginase 2 (ARG2) (26). Various other 
signals, including IL-10, TGF-β, CSF1, and IL-6, induce diverse 
polarization schemes that fall under the M2 category because of 
their capacity to downregulate, protect, or repair in response to 
inflammation (27). Owing to the functional diversity of tissue 
macrophages, the model further expanded to M2a, M2b, and 
M2c classifications (28); however, recent advances in transcrip-
tomics dispute the M1/M2 dichotomy (29), and it seems likely 
that macrophage activation represents a wide spectrum of very 
distinct responses (30).
Macrophage nomenclature was adopted to describe the dif-
ferent functional states of microglia (31). M1 microglia produce 
cytokines and chemokines (IL-1β, IL-6, IL-12, TNF-α, CCL2), 
express NADPH oxidase, and generate reactive oxygen and nitro-
gen species. Additionally, M1 microglia express MHC-II, integrins 
(CD11b, CD11c), costimulatory molecules (CD36, CD45, CD47), 
and Fc receptors. M2 microglia produce antiinflammatory cyto-
kines (IL-10, TGF-β), growth factors (IGF-1, FGF, CSF1), and 
neurotrophic growth factors (nerve-derived growth factor [NGF], 
brain-derived neurotrophic factor [BDNF], neurotrophins, glial 
cell–derived neurotrophic factor [GDNF]) (32).
Despite providing valuable insights into myeloid cell complex-
ity, transcriptome analysis of microglia derived from models of 
neurodegenerative diseases failed to show any clear-cut M1 or M2 
signature. Instead, they found simultaneous expression of both M1 
and M2 markers, suggesting the presence of mixed phenotypes 
or the lack of an activation signature (13, 33–35). Transcriptome 
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Because aging is the primary risk factor for AD, its prevalence is 
increasing with growth of the elderly population. Estimates indi-
cate that AD affects more than one-third of the population over the 
age of 85 (40), posing an enormous socioeconomic burden. Avail-
able treatments only manage symptoms, and there is a need for 
therapeutics that halt or reverse the disease’s underlying pathology.
AD is typified by distinct tissue changes associated with 
accumulation of extracellular amyloid-β (Aβ) peptides, derived 
from the cleavage of amyloid precursor protein (APP), and intra-
cellular deposits of hyperphosphorylated tau. Genetically, AD 
is divided into familial (FAD) and sporadic forms. Fewer than 
about 5% of patients are affected by FAD (40) due to mutations 
in APP, presenilin-1, or presenilin-2 (41–43), which increase 
either the levels or aggregation propensity of Aβ. Sporadic AD 
is strongly associated with apolipoprotein E ε4 (APOE4) expres-
sion, whereas APOE2 expression is protective (44). Astrocytes 
and microglia express APOE under the control of nuclear hor-
mone receptors, and it plays an important role in Aβ phagocy-
tosis by microglia (45), although it may influence AD through 
multiple mechanisms. The balance between Aβ production and 
removal seems to determine amyloid burden in AD brain (46), 
and dysregulated Aβ clearance rather than increased Aβ pro-
duction has been linked to the etiology of sporadic AD (47). As 
resident phagocytes of the CNS, microglia are primarily respon-
sible for phagocytotic clearance of Aβ by or local Aβ degradation 
through the release of degrading enzymes (48), although other 
clearance mechanisms are involved (49).
data showed that microglia in the context of neurodegenerative 
diseases express both neurotoxic and neuroprotective factors as 
well as genes involved in stress responses, misfolded proteins, 
and neuronal damage. In light of these findings, M1/M2 polariza-
tion states identified in vitro are simplistic and do not model the 
in vivo conditions that involve continuous reciprocal interactions 
between microglia and surrounding CNS structures. Further, given 
the evidence on microglia origins and versatile functions, the M1/
M2 polarization view derived from the periphery may not translate 
to CNS (36). For example, the M1/M2 paradigm does not account for 
the role of proliferating microglia (37). Furthermore, while transcrip-
tome studies have identified new markers selectively expressed on 
microglia, including the purinergic receptor P2Y12, transmembrane 
protein 119 (TMEM119), the chemokine receptor CX3CR1, and 
Siglec-H, other cell types may also display these markers (38, 39). 
Recently, Grabert and colleagues showed regional microglial hetero-
geneity in young mice, with the greatest convergence between cer-
ebellar and hippocampal microglia in terms of immunoregulatory- 
and bioenergetics-related transcripts compared with cortex and stri-
atum. Interestingly, aging was associated with diminished distinc-
tions between hippocampus compared with striatum or cortex (13). 
The cause or impact of these changes in microglial heterogeneity in 
space or time remains to be further elucidated.
Alzheimer’s disease
Alzheimer’s disease (AD) is the most common type of dementia 
associated with progressive cognitive decline and memory loss. 
Figure 1. Acute versus chronic activation of microglia in AD. Aβ binds to PRRs, leading to activation of resting microglia. Acutely activated microglia express 
cytokines, which drive enhanced phagocytosis, uptake, and clearance of Aβ. Long-term activation of microglia drives proliferation as well as a chronic inflamma-
tory state that causes neurotoxicity and neurodegeneration. Sustained activation of microglia, induced by brain trauma, systemic inflammation, obesity, and 
reduced physical activity, also drives neurotoxicity and neurodegeneration. DAMPs that arise from these processes further activate microglia, leading to compro-
mised Aβ phagocytosis and propagating chronic inflammation. Chronic inflammation and accumulation of Aβ are well-established clinical features of AD.
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contrast, chronic activation of microglia contributes to neurotox-
icity and synapse loss by triggering several proinflammatory cas-
cades. Microglia express pattern recognition receptors (PRRs), an 
evolutionarily conserved family of innate immune cell receptors 
that are designed to respond to danger- or pathogen-associated 
molecular patterns (DAMPs or PAMPs). PRRs bind to different 
species of Aβ with various affinities (71). A recent study showed 
that under certain circumstances in human AD cortex, high- 
molecular-weight Aβ species dissociate into small neurotoxic 
oligomeric Aβ species, and administration of the latter to mice 
activates microglia in vivo. These activated microglia were char-
acterized by increased microglial CD68 levels and decreased ram-
ification (72). In vitro, Aβ activates microglia by binding to PRRs, 
including receptors for advanced glycation end products (RAGE) 
(73), TLRs (74), and scavenger receptors (75, 76). Importantly, 
upon PAMP or DAMP binding to PRRs, the enhanced production 
of proinflammatory cytokines such as IL-1β and TNF-α and other 
inflammatory mediators compromises microglial phagocytosis 
(77, 78). Interestingly, the microglia cytokine expression profile 
seems to influence the microglia phagocytotic index. Microglia 
producing IL-1α and IL-1Rα showed a higher phagocytic index and 
Aβ load than microglia that did not produce these cytokines. Inter-
estingly, TNF-α– and IL-1β–producing microglia were abundant in 
APP/PS1dE9 AD model mice and were associated with lower Aβ 
load and phagocytic index (79). However, most experimental data 
concerning microglial Aβ phagocytosis published to date must be 
considered with great care, as the assays used measured mostly 
uptake but not intracellular Aβ degradation. Importantly, during 
neurodegeneration, additional DAMPs may arise, including but 
not restricted to chromogranin A (80) or myloid–related protein 
14 (MRP14) (81), which by themselves can activate microglia and 
compromise phagocytic clearance. It is likely that such factors, 
together with accumulating Aβ, are responsible for the chronic 
neuroinflammation observed in AD.
Loss of inhibitory signals
Under physiological conditions, microglia retain a neural-specific 
phenotype (82) and remain in a relatively quiescent state due to 
mutual exchange of neuronal and astrocytic signals (83, 84). Neuron- 
microglial inhibitory interactions are facilitated by binding of a 
variety of neuronal immunomodulators to their cognate receptors 
expressed predominantly on microglia, such as CD200/CD200R 
(85, 86), CX3CL1 (fractalkine)/CX3CLR1 (87, 88), CD22/CD45 
(89), CD172A/CD47 (90), CD95/APO-1, and ICAM5/lymphocyte 
function–associated antigen-1 (LFA1) (91). Dysregulated neuron- 
microglia communication has been implicated in neurodegen-
erative diseases (92). Studies using murine models of AD have 
demonstrated that chemokine receptors influence AD pathology by 
modulating several aspects of microglial function, such as accumu-
lation, clustering, and phagocytosis (93–96). Loss of the chemokine 
receptor CXCR3 in APP/PS1 mice reduced Aβ burden and inflam-
mation while increasing BDNF expression and improving behavioral 
deficits (95). Thus, CXCR3 signaling is involved in the suppression 
of microglial Aβ phagocytosis in APP/PS1 mice, ultimately lead-
ing to an increase of Aβ plaque deposition. In contrast, CX3CL1 or 
CX3CR1 deficiency promoted microglial phagocytosis of Aβ (96, 97). 
However, CX3CL1 deletion increased tau phosphorylation (97), sug-
Cumulative evidence indicates that Aβ and tau aggregates are 
neurotoxic and trigger neurodegenerative processes in the brain, 
suggesting that Aβ and tau are central for driving AD pathogene-
sis (50–53). Interestingly, APOE4 expression was associated with 
enhanced Aβ production, driven by increasing APP expression 
in neurons (54). Additionally, recent GWAS link several immune 
genes, particularly complement receptor-1 (CR1), CD33, and 
triggering receptor expressed on myeloid cells-2 (TREM2), with 
increased AD risk (55). Furthermore, a network-based integrative 
analysis of AD-related genes revealed that an immune/microglial 
gene network had the strongest association with AD neuropathol-
ogy (56). These findings raise the possibility that innate immune 
activation may actively contribute to AD pathogenesis, rather than 
arising as a pure bystander reaction to amyloid deposition, as pre-
viously assumed (57).
Microglia activation in AD
Microglia mount an acute immune response in the brain against 
harmful stimuli, including misfolded proteins such as Aβ. If the 
response does not resolve, the chronic activation of microglia 
diverts their physiological and beneficial functions (Figure 1). 
Activated microglia along with immunoglobulins and comple-
ment components are closely associated with Aβ deposits in brains 
from AD patients and AD mouse models (58–62). For example, 
activated microglia in AD show increased proliferation (63, 64) 
and increased expression of inflammatory markers such as CD36, 
CD14, CD11c, MHC-II, and iNOS (65, 66), as well as markers 
of the M1 phenotype. However, a new phenotype of microglia, 
referred to as “dark microglia,” was found in conditions such as 
chronic stress, including in the APP/PS1 mouse model of AD. 
Notably, dark microglia exhibited a highly activated phenotype 
with strong expression of CD11b and TREM2 and extensive encir-
cling of synaptic clefts when the microglia were associated with 
amyloid deposits (67). This observation suggests the presence of 
multiple microglial phenotypes with distinct functions.
It is well known that trans-synaptic propagation of tau occurs 
through anatomically connected synapses. However, microglia 
also were implicated in spreading tau aggregates through endocy-
tosis (via phagocytosis) and exocytosis (via exosomes) in a non-
synaptic transmission pathway (68). Depletion of microglia sup-
pressed tau propagation (68), suggesting that microglia actively 
contribute to tau pathology during AD pathogenesis. Moreover, 
microglia may indirectly contribute to neuronal demise through 
regulation of neighboring astrocytes. Microglial-derived immune 
factors can induce a so-called A1 astrocyte phenotype that contrib-
utes to neuronal death through reduced trophic support, impaired 
clearance capacity, and release of toxins (69).
Microglial activation induces several dynamic changes, 
including morphological alterations, such as shortening of the 
processes and swelling of the soma, changes in surface phenotype 
and secretory profile, and increased proliferative responses (70). 
Grouping of these distinct cellular and biochemical features under 
the term “activation” may obscure the beneficial and detrimental 
outcomes of microglial responses. In AD pathogenesis, microg-
lia activation may play a dual role: on one side, acute microglial 
activation in some experimental paradigms leads to decreased 
Aβ accumulation by increasing phagocytosis or clearance. In 
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might suffer a subsequent decline. Thus, a detailed longitudinal 
characterization of microglia activation in relation to AD patho-
genesis is needed. This will be important for determining the ther-
apeutic outcome of immunotherapy.
Toll-like receptors
TLR4, TLR1, TLR2, TLR9, their coreceptors CD14 and CD36, and 
NOD-like receptors such as the NLRP3 inflammasome are among 
the well-characterized PRRs in AD subjects and related murine 
models of AD. TLRs bind both fibrillar and oligomeric forms of 
Aβ (74). Increased expression of Tlr2, Tlr4, Tlr5, Tlr7, and Tlr9 
mRNAs was found in Aβ plaques, and expression of Tlr2/5 was 
elevated in plaque-associated tissue in comparison with plaque-
free tissue (107), suggesting a topographic TLR distribution in 
association with AD pathology. Stewart and colleagues demon-
strated that Aβ-mediated release of proinflammatory factors and 
neurotoxicity partially involved signaling through the CD36/
TLR4/TRL6 complex (108). Importantly, studies elucidating 
the role of TLRs in microglial activation have yielded conflicting 
results (109). APP/PS1dE9 mice lacking functional TRL4 showed 
an increase in Aβ load associated with decreased expression of 
IL-1β, CCL3, and CCL4 and decreased cognitive function (110), 
suggesting a protective role of TRL4 in amyloid clearance. Simi-
larly, a single intrahippocampal injection of LPS, a well-defined 
TLR4 agonist, boosted amyloid clearance in APP mice. This clear-
ance was associated with a transient increase in proinflammatory 
mediators (111), which may be positively involved in this clearance 
reaction. In contrast, studies of acute (109) and chronic LPS expo-
sure reported accelerated amyloidosis and increased microglial 
activation that localized to plaques in LPS-treated brains (112, 
113). Chronic LPS challenge could potentially induce tolerance, 
which may shift the microglial state from promoting clearance to 
accelerating deposition.
Mice lacking the TLR2/4 coreceptor CD14 exhibited a reduc-
tion in amyloidosis and CD45 and ionized calcium–binding 
adapter-1 (IBA1) immunoreactivity. Interestingly, this was associ-
ated with an increase in M1 markers such as TNF-α and IFN-γ, a 
decrease in M2 markers including Fizz1 and YM1, and, paradoxi-
cally, an increase in the M2-associated marker IL-10 (114). These 
findings suggested that CD14 deletion shifts microglia activation 
to an immunomodulatory state, possibly by blocking TLR2 signal-
ing, which contributes to inflammation and AD pathology (115). A 
drawback of TLR4 stimulation was the observed increase in tau- 
related pathology in 3xTgAD and rTg4510 mice (109). Based on 
these findings, Scholtzova and colleagues tested TLR9 stimulation 
with CpG-containing oligodeoxynucleotides (CpG-ODNs) in mice, 
demonstrating that repeated monthly injections of CpG-ODNs 
reduced amyloid deposition and cerebral amyloid angiopathy, 
and prevented cognitive deficits. In contrast to TLR4 stimulation, 
TLR9 stimulation decreased tau-related pathology (116). With 
regard to microglial activation, overall levels of CD45, CD206, and 
CD11b were reduced in mice treated with CpG-ODNs, although 
microglia within the few remaining amyloid deposits showed 
increased CD45 reactivity (117). Plasma levels of both pro- and 
antiinflammatory cytokines were elevated; importantly, IL-1β, 
previously associated with increased tau pathology, remained 
unchanged (117). Likewise, a single i.c.v. injection of CpG-ODNs 
gesting that the divergent effects of CX3CL1 signaling in AD pathol-
ogy should be considered for pharmacological targeting of neuroim-
munomodulators. In addition to surface receptor interaction, neurons 
may also modulate microglial function and structure through the 
release of neurotransmitters. For example, tyrosine hydroxylase+ 
(TH+) neurons in the locus coeruleus (LC), a small brainstem nucleus, 
regulate microglial mediator release and Aβ clearance in their projec-
tion areas, including the hippocampus and neocortex, through the 
release of norepinephrine (98). In turn, early LC degeneration and 
subsequent loss of norepinephrine in the respective brain regions per-
mit increased immune responses and Aβ accumulation (99).
Multifaceted immune activation
In vivo imaging shows that microglia activation precedes the onset 
of AD (100) and is paralleled by increased levels of inflammatory 
markers in the cerebrospinal fluid (101), supporting the idea that 
inflammation occurs early in AD pathogenesis. In patients with 
mild cognitive impairment (MCI), a prodromal stage of AD, 
reductions in microglial activation were observed after a 2-year 
follow-up. In contrast, AD patients showed an increase in microg-
lial activation (102). Interestingly, in MCI, microglial activation 
was positively correlated with cognition and gray matter volume, 
suggesting that microglial activation plays a protective role in 
the early phase of clinically apparent disease (100). In contrast, 
microglial activation correlated with glucose hypometabolism in 
AD patients (103), suggesting a link between microglial activation 
and synaptic dysfunction. Taken together, the authors suggested 
a bimodal distribution of microglial activation in the trajectory 
of AD, with an early protective peak at the preclinical/prodromal 
stage and a later cidal proinflammatory phenotype peaking at the 
clinical stage (102).
This hypothesis is supported by the findings of the Alzhei-
mer’s Disease Anti-inflammatory Prevention Trial (ADAPT), in 
which patients were stratified into three phases depending on 
their level of cognitive decline. This stratification reasoned that 
patients with a fast decline in cognition would probably be closer 
to clinically apparent AD than those with little or no cognitive 
decline (104). Furthermore, epidemiological studies supported 
that NSAIDs decrease the development of AD (105). Their main 
targets were cyclooxygenase enzymes: constitutively expressed 
COX-1 and inflammation-induced COX-2. Interestingly, the 
COX-1 inhibitor naproxen was beneficial in fast decliners only; in 
contrast, the selective COX-2 inhibitor celecoxib was beneficial in 
slow decliners but harmful in the fast-progressing group. COX-2 
expression peaks in neurons in Braak phases 0–II (an early stage 
characterized by neurofibrillary changes beginning at transen-
torhinal regions), probably representing an adaptive response 
that subsequently declines (105). Thus, COX-2 blockade in early 
phases may be harmful, whereas COX-1 inhibition (in addition 
to COX-2 inhibition) may be beneficial, as COX-1 expression in 
microglia increases during Braak phases III–IV (when the neuro-
fibrillary tangles spread to the hippocampus) (105), although this 
does not exclude the possibility of other mechanisms. However, in 
the clinical phase of AD, the strong association between microglial 
activation and AD pathology was observed in young AD patients, 
but activation waned in AD patients older than 80 years (106), 
suggesting that the immune activation state in the trajectory of AD 
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phagocytosis. Chronicity could be another factor that influenc-
es the role of complement in AD. For example, acute C3 exposure 
increased microglial phagocytosis in vitro, while chronic exposure 
diminished microglial phagocytosis (125), suggesting that chronic 
Aβ load may divert initial phagocytosis-promoting mechanisms to 
mechanisms that promote deposition. Thus, complement’s role in 
AD pathogenesis needs to be examined further, taking into account 
disease phase and the particular targets being considered for thera-
peutic intervention.
Cytokines
Another approach to manipulate microglial responses to Aβ was 
to regulate cytokine levels. IL-1β, a key cytokine of the innate 
immune response, was shown to enhance Aβ pathology (126), as 
well as increase tau pathology (109). Moreover, mice overexpress-
ing IL-6 (127) or IFN-γ (128) had enhanced microglial phagocyto-
sis of Aβ accompanied by an increase in complement component 
mRNA levels, TNF-α, and other inflammatory mediators. TNF 
receptor (TNFR) deficiency in 3xTgAD mice was associated with 
increased amyloid deposition and enhanced tau phosphorylation 
(129). Moreover, microglia from TNFR-deficient 3xTgAD mice 
showed defective phagocytosis, highlighting the protective role of 
TNF-α in facilitating clearance mechanisms. These studies suggest 
that a perpetual proinflammatory environment in the context of Aβ 
deposition may have beneficial outcomes. However, the inhibition 
of proinflammatory response, including loss of NLRP3 inflam-
masome, myeloid-related protein-14 (MRP14), and IL-12 and IL-23 
signaling, has also been beneficial in reducing amyloid pathology 
(130). The NLRP3 inflammasome is critical for maturation of IL-1β, 
and loss of NLRP3 in APP/PS1 decreased amyloid burden (131).
The innate immune system can be harnessed to clear Aβ in 
the context of antiinflammatory cytokines. IL-10 levels are ele-
vated in AD brain, and IL-10 overexpression in mice increased 
APOE expression in addition to worsening AD-related pathology 
and cognitive impairment (132). Il10 deletion led to increased 
Aβ phagocytosis and increased CD68 reactivity in Aβ deposit– 
associated microglia (133). Thus, cytokines could serve as poten-
tial therapeutic targets to modulate microglial responses. Antibod-
ies targeting proinflammatory cytokines such as IL-1, IL-6, or their 
receptors are used in the treatment of autoimmune diseases and 
may have beneficial effects in AD; however, the precise window 
of opportunity and ideal cytokine target still need to be identified.
Microglia proliferation
Microglial activation during injury involves recruitment of cells, 
mainly through local proliferation of resident microglia, followed 
by a wave of apoptosis to reduce the levels to baseline (134). Lit-
tle is known about microglial proliferative responses in the brain. 
Increased microglial proliferation has been described in the brains 
of AD patients (135), and in the prodromal stage of Parkinson 
disease (136), suggesting that microglial proliferation is an early 
event in the course of neurodegenerative diseases. Increased 
microglial proliferation was observed in several murine AD mod-
els (63), appearing with plaque onset and persisting for 18 months 
(63). In mice, approximately 50% of the proliferating microg-
lia were found near Aβ deposits (63), whereas in human AD, the 
majority of plaque-associated microglia were not proliferating 
decreased the cerebral Aβ load and rescued deficits in fear con-
ditioning (118). Another interesting comparison of TLR4 and 
TLR9 manipulation is the transient nature of the TLR9-associated 
inflammatory response. Longitudinal assessment of TLR4 stim-
ulation revealed a transient increase in proinflammatory markers 
such as IL-1β and TNF-α, and in microglia it transiently increased 
TLR4, CD45, CR3, scavenger receptor A (SR-A/CD204), and Fcγ 
receptor immunoreactivity in the brain (111). Although the levels of 
all markers analyzed returned to baseline within a week, microglial 
CD45 and CR3 levels remained elevated at 28 days after injection. 
In contrast, 12 hours after TLR9 stimulation, CD45, CD11b, and 
CD206 levels remained elevated, but there was an overall reduc-
tion in these markers with the longitudinal stimulation regimen 
(117). These observations indicate that a transient surge in proin-
flammatory mediators that eventually subsides might be beneficial 
in promoting clearance without driving excessive inflammation. 
Interestingly, a polymorphism in the TLR9 promoter was asso-
ciated with decreased AD risk, and further analysis of peripheral 
blood monocytes suggested that the polymorphism was associated 
with increased TLR9 expression (119). Hence, it seems that TLR9 
stimulation activates an innate immune response that benefits AD 
pathology without provoking inflammation.
Complement system
Given the role of microglia and complement in synaptic pruning and 
the identification of a CR1 gene variant that is linked to an increased 
risk for AD (17, 120), complement-mediated microglial phagocyto-
sis of synapses may contribute to AD pathogenesis. Accordingly, 
Hong and colleagues demonstrated that microglia in concert with 
complement caused early synapse loss when challenged with oligo-
meric Aβ (121). Before the onset of Aβ deposition, microglia engulf 
synapses opsonized with the complement factors C1q and C3 upon 
CR3-mediated recognition of C3 (121). Blocking of C3, C1q, or CR3 
rescued this early synapse loss in APP/PS1 mice (121). However, 
other studies have reported that inhibition of different components 
of complement impaired Aβ phagocytosis, resulting in elevated syn-
apse loss. In a mouse model of AD, overexpression of soluble comple-
ment component 3b/4b receptor 1–like (CRRY; a complement inhib-
itor in rodents) (122), C3 deficiency (123), or blocking of C5a (124), 
a downstream component of the complement cascade, increased 
Aβ levels in the absence of increased Aβ production, reflecting the 
role of complement in microglial phagocytosis. In the same stud-
ies, complement blockade was associated with increased neurode-
generation. In contrast to these observations, Lian and colleagues 
demonstrated that Aβ induced release of C3 from astrocytes and 
impaired microglial Aβ phagocytosis (125). Inhibition of microglial 
C3aR reduced microglial activation and augmented Aβ clearance 
in the brain (125), suggesting a detrimental role for complement. 
Interestingly, the Hong et al. study associated the C3 comple-
ment cascade with increased microglial phagocytosis of synapses 
in an early phase of AD, prior to Aβ deposits (121), whereas Lian and 
colleagues demonstrated C3-mediated impairment of microglial 
phagocytosis during robust Aβ pathology (125). In a report from 
Maier and colleagues, C3 deficiency was detrimental only during 
the late phase of AD in 17-month-old mice (123). The discrepancies 
among these studies underscore the impact of the precise disease 
time period on complement-mediated regulation of microglial 
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(137). In focal cerebral ischemia, proliferating microglia mediate 
neuroprotection via secretion of growth factors (138). Microglial 
proliferation in the brain peaked between 48 and 72 hours after 
injury (139), and selective ablation of proliferating microglia was 
associated with increased ischemic lesion size and neurodegen-
eration (138). In the absence of pathology, microglia proliferation 
increased in the cortex of mice subjected to environmental enrich-
ment and wheel running, and the proliferating microglia appeared 
ramified, without signs of activation (140).
Lawson and colleagues reported a microglial turnover rate 
of 0.05% at any given time in healthy brain (141), but recent data 
from the same group indicated a turnover rate of 0.69% (7). These 
data estimate that it takes approximately 96 days to renew the 
entire microglial population in mice, suggesting several cycles of 
microglial self-renewal during a mouse’s lifetime. The number of 
self-renewal cycles in the human brain was estimated to be around 
100 (7). This striking difference between human and mouse sup-
ports the idea that rodent microglia may not experience patholog-
ical factors associated with aging such as senescence or dystrophy 
(70). These findings raise the question of how many cell divisions 
can occur before microglia suffer from critical shortening of telo-
meres and enter a senescent, dystrophic state. How do increased 
self-renewal cycles due to pathology influence the physiological 
functions of microglia? The role of microglia proliferation in rela-
tion to AD needs further examination.
Microglia receive signals for survival and proliferation follow-
ing stimulation of the CSF1 receptor (CSF1R) with CSF1 or IL-34 
(142). At the transcriptional level, the CEBP/α/PU.1 pathway is 
involved in the regulation of monopoiesis and granulopoiesis 
(143, 144) and serves as a candidate for regulating proliferation 
in microglia. Elevated expression of CSF1R pathway compo-
nents were found in the brains of AD patients. Furthermore, the 
expression of several proliferation and inflammation markers cor-
related with disease severity (64), suggesting a pathological role 
for microglia proliferation and activation in disease progression. 
Pharmacological inhibition of CSF1R in mice upregulated anti-
inflammatory mediators, including IL-4, IL-5, IL-13, and CCL9, 
and increased synapse and spine densities while reducing proin-
flammatory cytokine levels (64). Although targeting CSF1R has 
therapeutic potential, caution should be taken, as CSF1R haplo-
insufficiency was linked to adult-onset leukoencephalopathy with 
axonal spheroids and pigmented glia (145). Additionally, CSF1R 
signaling in a selected neuron population, rather than in microglia, 
provides neuroprotective and survival signals in the neurodegen-
eration setting (146).
TREM2
Triggering receptor expressed on myeloid cells-2 (TREM2) is abun-
dantly expressed on microglia. Allelic variants of TREM2 confer high 
risk for developing sporadic AD; therefore, research into TREM2’s 
function has gained momentum. TREM2 has many ligands, includ-
ing phospholipids and sulfatides, which are exposed on apoptotic 
or damaged cells, lipoprotein particles such as HDL and LDL, and 
APOE. TREM2 promotes phagocytosis of apoptotic neurons, prolif-
eration, and survival of microglia, and has been implicated in damp-
ening TLR-induced inflammatory responses (147–151). Addition-
ally, TREM2 deficiency impairs microglial phagocytosis of plaques 
opsonized with anti-Aβ antibodies, suggesting a critical role for 
TREM2 in the efficacy of antibody-based therapeutics (152). Stimu-
lation of nuclear receptor signaling with the retinoid X receptor ago-
nist bexarotene induces the TREM2 expression in microglia (153). 
TREM2+ microglia show increased expression of phagocytic mark-
ers, suggesting that these microglia are phagocytic. Given that APOE 
binds TREM2, one may speculate that APOE increases phagocytosis 
of Aβ by enhancing TREM2 signaling.
AD risk variants in TREM2 impair the cell surface transport 
and expression of TREM2; some variants either impair or mark-
edly enhance the binding of TREM2 to phospholipids, suggesting 
that balanced TREM2 function in AD is important to counteract 
disease progression (147). TREM2 levels were elevated in the 
microglia of AD patients, particularly in microglia associated with 
plaques and neurofibrillary changes, and TREM2 levels correlated 
with markers of neurodegeneration (154), suggesting a pathogenic 
role for TREM2.
Studies on TREM2 deficiency in AD mice have produced 
conflicting results, with reports that Aβ pathology could be either 
increased or decreased. TREM2 was upregulated in CD45hiLyC+ 
myeloid cells surrounding the amyloid plaques, but not in paren-
chymal P2Y12+ microglia (155). TREM2 deficiency eliminated 
plaque-associated CD45hiLyC+ myeloid cells, leading to reduced 
inflammation and AD-like pathology in these mice (155); however, 
TREM2-expressing myeloid cells were enriched in microglia pro-
cesses contacting amyloid deposits in AD mice, and TREM2 dele-
tion resulted in less compact plaques and increased dystrophic 
neurites. Similarly, TREM2 silencing in P301S mice increased tau 
pathology and synapse loss and enhanced the proinflammatory 
cytokine levels in the brain (156). A recent report indicated that 
the opposing results from previous work might reflect a disease 
progression–dependent influence of TREM2 deficiency on AD 
pathology. While TREM2 deficiency in young APP/PS1-21 mice 
ameliorated amyloid pathology, it enhanced amyloid deposition 
at later disease stages (157). Additionally, TREM2 deficiency in 
aged mice decreased plaque-associated myeloid cell accumu-
lation by reducing proliferation (157). Considering the dual role 
of TREM2, a longitudinal assessment of TREM2 in conditional 
knockout models will reveal important effects of TREM2 signaling 
on myeloid cells during AD progression to support development of 
TREM2-directed therapeutics for different disease stages.
Optogenics in activation of microglia
Gamma oscillations arise from the activation of local circuits of 
excitatory and fast-spiking inhibitory neurons resonating at 20–50 
Hz, and changes in gamma oscillation have been observed in neu-
rological diseases (158). Interestingly, entraining gamma oscilla-
tion at 40 Hz in 5xFAD mice induced amyloid reductions that were 
associated with an increase in microglial numbers and morphologi-
cal changes such as soma enlargement and shortening of processes 
loaded with Aβ. RNA sequencing analysis showed an increase in 
phagocytic genes, such as Cd68, β2-microglobulin (B2m), Icam, 
and lysozyme 2 (Lyz2), and in the proliferation markers Csf1, Csf1r, 
and Csf2ra. Notably, levels of proinflammatory genes (Il1b, Il6, 
Cd11b) and antiinflammatory genes (Igf1) were not changed (158), 
suggesting that it is possible to use immunomodulation to polarize 
microglia toward a beneficial activation state that is characterized 
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by increased phagocytic activity without the induction of sustained 
inflammatory responses. Further studies are needed to evaluate 
the therapeutic potential of gamma oscillation in human AD.
Concluding remarks
Although the data are not fully consistent, they strongly suggest 
that microglia could be mobilized to promote Aβ clearance and 
reduce amyloid deposition through multiple mechanisms. Given 
that age has a dramatic impact on innate immunity and represents 
a major risk factor for AD, more longitudinal studies need to be 
performed and the overall outcome of immune modulation needs 
to be tested in aged animals. A plethora of evidence supports the 
dual nature of neuroinflammation in the early versus the late 
phases of AD. Additionally, the M1 or M2 microglia phenotypes 
could have a detrimental or beneficial outcome depending on the 
disease context, and more detailed analysis is required. Addition-
ally, in vivo human studies, informed by animal models, will help 
better characterize the role of microglia activation in the dynamic 
stages of the disease. Interestingly, microglia seem to be inti-
mately involved in the propagation of tau pathology; however, it 
remains unclear whether microglia contribute to tau pathology 
by failing to phagocytize pathological tau or by releasing factors 
that exacerbate tau pathology. From a therapeutic perspective, it 
will be interesting to identify the role of disease-specific microg-
lial phenotypes during the progression of AD to design immu-
notherapy that boosts or tempers inflammation depending on 
the precise disease stage. One limitation of current mouse mod-
els is the absence of clear neurodegeneration and human-like 
tau pathology unless the disease is induced by a tau mutation. 
It seems that combining human induced pluripotent stem cell 
(iPSC) technology (159) with recent advances in gene editing will 
provide new opportunities to model disease pathology that more 
closely resembles human AD.
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